Impact of histologic chorioamnionitis on pulmonary hypertension and respiratory outcomes in preterm infants

Sook Kyung Yum, Min-Sung Kim, Yoojin Kwun, Cheong-Jun Moon, Young-Ah Youn and In Kyung Sung
Division of Neonatology, Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Abstract
We aimed to evaluate the association between the presence of histologic chorioamnionitis (HC) and development of pulmonary hypertension (PH) during neonatal intensive care unit (NICU) stay. Data of preterm infants born at 32 weeks of gestation or less were reviewed. The development of PH and other respiratory outcomes were compared according to the presence of HC. Potential risk factors associated with the development of PH during NICU stay were used for multivariable logistic regression analysis. A total of 188 infants were enrolled: 72 in the HC group and 116 in the no HC group. The HC group infants were born at a significantly shorter gestational age and lower birthweight, with a greater proportion presenting preterm premature rupture of membrane (pPROM) > 18 h before delivery. More infants in the HC group developed pneumothorax (P = 0.008), and moderate and severe bronchopulmonary dysplasia (BPD; P = 0.001 and P = 0.006, respectively). PH in the HC group was significantly more frequent compared to the no HC group (25.0% versus 8.6%, P = 0.002). Based on a multivariable logistic regression analysis, birthweight (P = 0.009, odds ratio [OR] = 0.997, 95% confidence interval [CI] = 0.995–0.999), the presence of HC (P = 0.047, OR = 2.799, 95% CI = 1.014–7.731), and duration of invasive mechanical ventilation (MV) > 14 days (P = 0.015, OR = 8.036, 95% CI = 1.051–43.030) were significant factors. The presence of HC and prolonged invasive MV in infants with lower birthweight possibly synergistically act against preterm pulmonary outcomes and leads to the development of PH. Verification of this result and further investigation to establish effective strategies to prevent or ameliorate these adverse outcomes are needed.

Keywords
bronchopulmonary dysplasia, inflammation, mechanical ventilation

Date received: 24 September 2017; accepted: 30 January 2018

Pulmonary Circulation 2018; 8(2) 1–7
DOI: 10.1177/2045894018760166

Fetal exposure to antenatal inflammation has been studied to induce preterm labor, have diverse effects on innate immune system, and contribute to various neonatal outcomes in preterm infants. In particular, histologic chorioamnionitis (HC) is diagnosed based on presence of polymorphonuclear cellular infiltrates and is generally thought to have a superior reflection of antenatal inflammatory response, compared to clinical chorioamnionitis which is identified by characteristic maternal (increased leukocyte counts and C-reactive protein, uterine tenderness and foul odor of vaginal discharge, tachycardia, and fever) or fetal findings (fetal tachycardia). HC has been previously studied for its possible positive or negative effects on the development of lung diseases such as respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD) in preterm infants.
In the meantime, there have been few reports on the possible association between antenatal inflammation/chorioamnionitis and pulmonary hypertension (PH), in term infants or in animal models but not in preterm infants. PH is one of the most fatal neonatal pulmonary pathologies, and because these infants are thought to have a greater risk of death and a higher chance of respiratory condition exacerbation by an overwhelming infection even after survival, PH should be one of major concerns for clinicians and caregivers. Therefore, in the present study, we aimed to outline the association between HC and respiratory outcomes of preterm infants, with a particular focus on PH, during neonatal intensive care unit (NICU) stay.

Methods

Patient selection and study design

Retrospective data were collected for infants admitted to the NICU of Seoul St. Mary’s Hospital from November 2014 to February 2017. Preterm infants born at 32 weeks of gestation or less were included. Infants who did not have their mother’s placental pathology results were excluded. Other reasons for exclusion were incomplete data for antenatal history, major congenital anomalies or major intrauterine morbidity, lack of data for the first weeks of life as in outborn patients, and death before the 14th day of life.

Maternal and neonatal characteristics were collected including HC results, preterm premature rupture of membrane (pPROM) hours, maternal underlying morbidities, completion of antenatal steroid (ANS) cycle, other maternal infections (results obtained from microbial tests of vaginal, cerclage tip, amniotic fluid, or placental samples), and basic information concerning gestational age (GA), birthweight, and Apgar scores of the infants. HC was diagnosed when polymorphonuclear cells were present within the amnion or chorion, as previously described by Redline et al. Parameters associated with the respiratory outcomes such as RDS, surfactant instillation doses, pneumothorax, development and severity of BPD, duration of invasive mechanical ventilator (MV), need for home oxygen therapy, and development of PH were also obtained. PH was defined as the use of inhaled nitric oxide (iNO) or sildenafil due to severe oxygenation failure, in accordance with accompanied echocardiographic findings such as tricuspid valve regurgitation with right ventricle enlargement, right-to-left or bidirectional shunt through patent foramen ovale, and/or patent ductus arteriosus. For BPD, we followed the definition based on the most recent NICHD/NHLBI/ORD Workshop summary. Other supplemental data such as neonatal morbidities like hemodynamically significant patent ductus arteriosus (hsPDA), defined as PDA requiring treatment due to clinical symptoms and signs implicating significant left-to-right ductal shunt like need for vasopressors, continued or increasing need for respiratory support, metabolic acidosis, oliguria, feeding intolerance, etc.; the detailed treatment strategy of our unit was fundamentally based on the clinical and echocardiographic criteria previously introduced by McNamara et al. which is described in previous study of ours, intraventricular hemorrhage (IVH) graded according to Papile’s criteria, and necrotizing enterocolitis (NEC) ≥ stage 2 of modified Bell’s criteria, and hospital course such as the length of stay, postmenstrual age (PMA) at discharge, and body weight at discharge were collected.

The above-collected parameters were compared between two groups depending on the presence of HC: HC group versus no HC group. Then potential risk factors—including HC—associated with the development of PH, which was the main outcome of our interest, were used in multivariable regression analysis model.

Statistical analysis

Continuous variables and categorical variables were compared between subgroups using Student’s t-test and chi-square or Fisher’s exact tests, as appropriate. Multivariable logistic regression analysis was executed in a backward conditional manner. A P value < 0.05 was considered statistically significant.

Ethical approval

The study was approved by the institutional review board of Seoul St. Mary’s Hospital.

Results

A total of 259 infants of GA ≤ 32 weeks were admitted to the NICU. Of these, 71 infants were excluded for the following reasons: (1) transferred in from other hospitals after 7th day of life (n = 11); (2) died within the first 14 days of life (n = 10); (3) major congenital anomaly or critical prenatal condition like hydrops fetalis (n = 9); (4) severe hypoxic ischemic encephalopathy (HIE) at birth (n = 1); (5) uncertain GA due to obscure antenatal history (n = 1); and (6) no histologic results for placenta or incomplete maternal data (n = 39). Thus, 188 infants were enrolled and divided into two groups according to the presence of HC (72 infants in the HC group versus 116 infants in the no HC group). The patient enrollment scheme is depicted in Fig. 1.

The basic demographics of the infants are described in Table 1. Infants in the HC group were significantly smaller in terms of GA and birthweight (both P < 0.001) and Apgar scores lower (P = 0.002 for 1-min Apgar and P = 0.020 for 5-min Apgar) compared to the no HC group. A significantly greater portion of infants in the no HC group were small-for-gestational-age (SGA), male, and had been delivered via Cesarean section. A greater percentage of the HC group infants had presented with pPROM > 18 h before delivery. Regarding maternal characteristics, a greater portion of mothers had presented with hypertension (P = 0.027) in the no HC group and had positive culture results for...
Ureaplasma urealyticum from vaginal samples \((P = 0.005)\). The completion of antenatal steroid cycle tended to be more prominent in the no HC group but did not show statistical significance.

Respiratory outcomes of the enrolled infants during NICU stay were compared (Table 2). Greater percentages of (but not statistically significant) infants in HC group had RDS and used ≥ 2 doses of surfactant compared to the no HC group. Only two infants (1.7%) in the no HC group developed pneumothorax while eight (11.1%) in the HC group did \((P = 0.008)\). Regarding BPD, almost a twofold percentage of the infants in the HC group presented both moderate and severe BPD compared to the no HC group \((P = 0.001\) and 0.006, respectively). The duration of invasive MV was also significantly longer in the HC group infants (median 17 days versus 4 days, \(P = 0.022\)). A significantly greater portion of HC group infants had used postnatal steroid for treatment of BPD (41.7% versus 24.3%, \(P = 0.013\)) and required home oxygen treatment (40.6% versus 24.5%, \(P = 0.026\)). PH in the HC group was also significantly greater in proportion when compared to the no HC group (25.0% versus 8.6%, \(P = 0.002\)).

A supplemental analysis for outcomes other than respiratory morbidities was also executed (Table 3). Overall morbidities and mortality did not show statistical significance between the HC and no HC groups. Only the length of hospital stay presented a significant difference, but PMA or body weight at discharge did not satisfy statistical disparity.

Since our greatest interest was whether HC was potentially associated with the development of PH in preterm infants, variables—including HC—with known or possible association with PH development during NICU stay were included in the multivariable logistic regression analysis model (Table 4). Among the factors recruited for association with PH development, birthweight \((P = 0.009, \text{ odds ratio } [\text{OR}] = 0.997, 95\% \text{ confidence interval } [\text{CI}] = 0.995–0.999)\), the presence of HC \((P = 0.047, \text{ OR} = 2.799, 95\% \text{ CI} = 1.014–7.731)\), and duration of invasive MV > 14 days \((P = 0.015, \text{ OR} = 8.036, 95\% \text{ CI} = 1.051–43.030)\) were significant factors.

The clinical characteristics of the PH infants during NICU stay are as follows. Twenty-eight infants received treatment for PH at any time during NICU stay. PH was diagnosed as early as the first day of life and as late as the 216th day of life (median = 11th day of life). All but one infant received inhaled NO therapy. Six infants received sildenafil (2–3 mg/kg per dose every 8–12 h) and nine infants received intravenous milrinone (0.25–0.75 mcg/kg/min) titrated according to clinical symptoms and echocardiographic findings. Twenty-four of the PH infants had severe BPD; 17 of these required home oxygen therapy. Five infants died before discharge from NICU and two infants who had failed repeated trials of extubation were transferred to the pediatric intensive care unit on ventilator.

**Discussion**

Based on our results, respiratory morbidities, including PH, were significantly more frequently encountered in infants with HC. Furthermore, birthweight, HC, and duration of invasive MV > 14 days were significant factors associated with the development of PH during NICU stay.
Table 1. Demographics of the enrolled infants according to the presence of histologic chorioamnionitis (HC).

|                          | HC (n = 72) | No HC (n = 116) | P value |
|--------------------------|------------|----------------|---------|
| Gestational age (weeks)  | 27.6 (25.5–29.8) | 30.4 (28.6–31.8) | <0.001  |
| Birthweight (g)          | 1058 (803–1309) | 1400 (953–1719) | <0.001  |
| 1-min Apgar              | 2 (1–4)     | 4 (2–5)         | 0.002   |
| 5-min Apgar              | 6 (4–7)     | 6 (5–8)         | 0.020   |
| SGA                      | 4 (5.6)     | 21 (18.1)       | 0.014   |
| Male                     | 30 (41.7)   | 66 (56.9)       | 0.042   |
| C/S delivery             | 60 (83.3)   | 109 (94.0)      | 0.019   |
| pPROM > 18 h             | 22 (30.6)   | 17 (14.7)       | 0.009   |
| Maternal age (years)     | 32 (30–36)  | 33 (31–35)      | 0.510   |
| Maternal diabetes        | 5 (6.9)     | 4 (3.4)         | 0.307*  |
| Maternal hypertension    | 8 (11.1)    | 28 (24.1)       | 0.027   |
| Placental abruption      | 6 (8.3)     | 8 (6.9)         | 0.715   |
| Maternal ureaplasma      | 55 (76.4)   | 65 (56.0)       | 0.005   |
| Antenatal steroid        | 26 (36.1)   | 56 (48.3)       | 0.102   |
| Other maternal infection | 21 (29.2)   | 21 (18.1)       | 0.077   |

Table 2. Respiratory outcome of the enrolled infants during NICU stay according to the presence of histologic chorioamnionitis (HC).

|                          | HC (n = 72) | No HC (n = 116) | P value |
|--------------------------|------------|----------------|---------|
| RDS                      | 66 (91.7)  | 96 (82.8)      | 0.085   |
| Surfactant ≥ 2 doses      | 10 (13.9)  | 13 (11.2)      | 0.585   |
| Pneumothorax             | 8 (11.1)   | 2 (1.7)        | 0.008*  |
| Moderate-to-severe BPD    | 44 (61.1)  | 41 (35.3)      | 0.001   |
| Severe BPD               | 29 (40.3)  | 25 (21.6)      | 0.006   |
| Postnatal steroid        | 30 (41.7)  | 28 (24.1)      | 0.013   |
| Invasive MV (days)        | 17 (2–50)  | 4 (2–21)       | 0.022   |
| Invasive MV > 14 days     | 36 (50.0)  | 33 (28.4)      | 0.003   |
| Home oxygen therapy*     | 26 (40.6)  | 27 (24.5)      | 0.026   |
| PH during NICU stay       | 18 (25.0)  | 10 (8.6)       | 0.002   |

Data are presented as median (interquartile range) or n (%).
*Fisher’s exact test.
†Sixty-four infants in the HC group and 110 infants in no HC group were compared (patients who have expired or transferred to other hospital before discharge were excluded).

HC is known to be present in 45–60% of very low birthweight (VLBW) infants and increases the risk of spontaneous preterm labor and subsequent preterm birth.14–16 HC was present in approximately 38.1% of the infants enrolled in our study, which is rather lower than the above-mentioned incidence. The lower frequency may have been due to the enrollment criteria: we included infants based on GA criterion and not birthweight criterion. Shorter GA and smaller birthweight in the HC group infants are features consistent with literature, and they would have contributed to the lower Apgar scores. HC has been shown to be associated with poor fetal growth or early postnatal growth, yet the association has been inconsistent according to studies.17,18 The predominance of maternal hypertension19 may have been related with the greater portion of SGA infants in the no HC group in our study. More HC group infants had been born to mothers with positive Ureaplasma culture results.20

Based on our results, though insignificant, a greater percentage of HC group infants tended to have been diagnosed

Table 3. Other neonatal morbidities, mortality, and hospital course.

|                          | HC (n = 72) | No HC (n = 116) | P value |
|--------------------------|------------|----------------|---------|
| hsPDA                    | 21 (29.2)  | 25 (21.6)      | 0.238   |
| Severe IVH               | 13 (18.1)  | 20 (17.2)      | 0.908   |
| Cystic PVL               | 5 (6.9)    | 9 (7.8)        | 0.836   |
| NEC ≥ stage 2            | 8 (11.1)   | 7 (6.0)        | 0.212   |
| Death                    | 4 (5.6)    | 4 (3.4)        | 0.485*  |
| Hospital stay (days)†    | 63 (46–92) | 45 (30–62)     | 0.001   |
| PMA at discharge (weeks)‡| 36.9 (35.3–40.3) | 36.6 (35.3–38.4) | 0.147   |

Data are presented as median (interquartile range) or n (%).
*Fisher’s exact test.
†Sixty-four infants in the HC group and 110 infants in no HC group were compared (patients who have expired or transferred to other hospital before discharge were excluded).
‡Sixty-four infants in the HC group and 110 infants in no HC group were compared (patients who have expired or transferred to other hospital before discharge were excluded).

HC, histologic chorioamnionitis; hsPDA, hemodynamically significant patent ductus arteriosus; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; PMA, postmenstrual age; PVL, periventricular leukomalacia.

Table 4. Multivariable logistic regression analysis for evaluation of potential risk factors associated with development of PH.

|                          | P value | Odds ratio | 95% CI  |
|--------------------------|---------|------------|---------|
| Gestational age (weeks)  | 0.649   | 0.873      | 0.486–1.568 |
| Birthweight (g)          | 0.009   | 0.997      | 0.995–0.999 |
| HC                       | 0.047   | 2.799      | 1.014–7.731 |
| SGA                      | 0.903   | 1.145      | 0.128–10.230 |
| hsPDA                    | 0.888   | 1.080      | 0.371–3.147 |
| Pneumothorax             | 0.628   | 1.438      | 0.330–6.260 |
| Invasive MV > 14 days    | 0.015   | 8.036      | 1.501–43.030 |
| Moderate-to-severe BPD   | 0.290   | 2.695      | 0.429–16.939 |

BPD, bronchopulmonary dysplasia; HC, histologic chorioamnionitis; hsPDA, hemodynamically significant patent ductus arteriosus; MV, mechanical ventilation; PH, pulmonary hypertension; SGA, small for gestational age.
as having RDS or have received \( \geq 2 \) doses of surfactant instilled endotracheally. Through animal studies, prenatal inflammation has been known to cause lung maturation, and Watterberg et al. described that the incidence of RDS in preterm infants exposed to chorioamnionitis had decreased. However, some papers raised the possibility of alteration of surfactant composition, dysregulation of modulatory function against surfactant inhibitory proteins, and decreased responses to exogenous surfactant replacement therapy. Furthermore, the difference in GA and birthweight between the two groups may have contributed to the tendency of infants in the HC group to have experienced more severe respiratory failure. In addition, despite low frequency, an approximately fourfold more portion of HC group infants in our study had developed pneumothorax. Requirements for greater respiratory support for severe respiratory condition and more fragile lung parenchyma due to inflammation may be related to the difference in incidence of pneumothorax between the two groups.

We also identified from our study results the difference in duration of invasive MV and severity of BPD depending on the presence of HC. According to a recent systematic review, although less striking after adjusting by GA and birthweight, HC and BPD had still shown an association. Alveolar and vascular simplification caused by endotoxin-induced chorioamnionitis is associated with pulmonary inflammation, and becomes vulnerable to further inflammation by various postnatal second hits such as resuscitation, oxygen toxicity, prolonged invasive mechanical ventilation, and infection. Ikegami et al. showed that antenatal exposure to endotoxin augmented the postnatal inflammation in the lungs of ventilated preterm lambs. In addition to such experimental findings, several publications have presented the possible link between the presence of chorioamnionitis and an increased risk of BPD/PH, but HC—which would be the priming factor of aberrant pulmonary genesis and structuralization—and duration of invasive MV are typical examples of postnatal second hit and were also significant risk factors associated with the development of PH.

On the other hand, HC, a placental pathology finding like maternal vascular underperfusion (MVU) has emerged as another important factor potentially associated with the development of BPD and PH. Several reports enlightened the possible relationship of placental underperfusion and being SGA with the development of BPD and PH. However, we were not able to directly analyze this relationship, because the description of MVU in the retrospectively collected data was not detailed enough to include MVU in our analysis. Instead, BW:PW (birthweight-to-placental-weight) ratio, which in part is reflective of the placental perfusion status, was compared depending on the development of PH, and it was significant (median [interquartile range] = 2.255 [1.933–2.772] versus 3.098 [2.649–3.740], \( P < 0.001 \), data not shown).

In turn, being SGA was not associated with the development of PH in the multivariable analysis of our study. The cohorts in the previous publications were somewhat smaller in GA (<29–30 weeks compared to < 33 weeks in our study) and this difference might have contributed to the disparity between our and their findings. In addition, Nyp et al. reported that beyond being SGA at birth, impairment in linear and head circumference growth was associated with moderate-to-severe BPD. Therefore, being SGA at birth solely may not be enough when discussing
BPD and PH. Furthermore, according to Lio et al., the risk of BPD increased dramatically in SGA preterm infants given that placental insufficiency is the major cause of low birthweight. However, as mentioned above, the exact analysis involving placental findings of MVU or prenatal Doppler findings (as in Lio et al.’s study) were not included in our study. Instead, the BW:PW ratio was included and it did not significantly differ depending on being SGA (data not shown). Therefore, although the reason for a lack of association between being SGA and the development of severe BPD or PH cannot be concretely determined, the most probable explanation would be that the cause of SGA in our cohort may not be solely attributable to placental underperfusion.

Our study shares limitations of other retrospective publications for the lack of prospective nature and restricted number of enrolled infants, and it is yet not ripe to extrapolate our study results to other units before obtaining validation from more large-scale prospective studies. Since it was a study based on medical record review, we were not able to assess actual numerical values of various proinflammatory cytokines that potentially are associated with the severity of antenatal inflammation nor histologic lung vascular structure concerning the progression of PH. However, we believe that risk assessment for developing early or late PH and BPD, which are each one of the most difficult-to-treat-well and fatal newborn diseases, would be meaningful for both the parents and caregivers to predict, understand, discuss, and prepare how to handle adverse future prognosis. In conclusion, HC is possibly associated with development of PH during NICU stay. In preterm infants with lower birthweight, a longer duration of invasive MV potentially acts together with HC in a complicated manner and lead to developing PH in preterm infants. Insights into this association should encourage future investigations with a larger cohort of infants in a prospective manner, to verify our results, and hopefully to establish more tailored, effective strategies to prevent, mitigate, or treat adverse consequences due to inflammation.

Conflict of interest
The author(s) declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD
Sook Kyung Yum http://orcid.org/0000-0001-8589-3159

References
1. Kramer BW, Kallapur S, Newham J, et al. Prenatal inflammation and lung development. Semin Fetal Neonatal Med 2009; 14: 2–7.
2. Kunzmann S, Collins JJ, Kuypers E, et al. Thrown off balance: the effect of antenatal inflammation on the developing lung and immune system. Am J Obstet Gynecol 2013; 208: 429–437.
3. Redline RW. Inflammatory responses in the placenta and umbilical cord. Semin Fetal Neonatal Med 2006; 11: 296–301.
4. Watterberg KL, Demers LM, Scott SM, et al. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996; 97: 210–215.
5. Thomas W and Speer CP. Chorioamnionitis is essential in the evolution of bronchopulmonary dysplasia – the case in favour. Paediatr Respir Rev 2014; 15: 49–52.
6. Been JV, Rours IG, Kornelisse RF, et al. Chorioamnionitis alters the response to surfactant in preterm infants. J Pediatr 2010; 156: 10–15.
7. Woldesenbet M and Perlman JM. Histologic chorioamnionitis: an occult marker of severe pulmonary hypertension in the term newborn. J Perinatol 2005; 25: 189–192.
8. Polglase GR, Hooper SB, Gill AW, et al. Intrauterine inflammation causes pulmonary hypertension and cardiovascular sequelae in preterm lambs. J Appl Physiol 2010; 108: 1757–1765.
9. Jobe AH and Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723–1729.
10. McNamara PJ and Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007; 92: F424–427.
11. Yum SK, Moon CJ, Youn YA, et al. Echocardiographic assessment of patent ductus arteriosus in very low birthweight infants over time: a prospective observational study. J Matern Fetal Neonatal Med 2018; 31: 164–172.
12. Papile LA, Burstein J, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500g. J Pediatr 1978; 92: 529–534.
13. Walsh MC and Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33: 179–201.
14. Goldenberg RL, Hauth JC and Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000; 342: 1500–1507.
15. Redline RW. Placental inflammation. Semin Neonatol 2004; 9: 265–274.
16. Thomas W and Speer C. Chorioamnionitis: important risk factor or innocent bystander for neonatal outcome? Neonatology 2011; 99: 177–187.
17. Williams MC, O’Brien WF, Nelson RN, et al. Histologic chorioamnionitis is associated with fetal growth restriction in term and preterm infants. Am J Obstet Gynecol 2000; 183: 1094–1099.
18. Mestan K, Yu Y, Matoba N, et al. Placental inflammatory response is associated with poor neonatal growth: preterm birth cohort study. Pediatrics 2010; 125: e891–e898.
19. Xiong X, Demianczuk NN, Saunders LD, et al. Impact of preeclampsia and gestational hypertension on birthweight by gestational age. Am J Epidemiol 2002; 155: 203–209.
20. Sweeney EL, Dando SJ, Kallapur SG, et al. The human Ureaplasma species as causative agents of chorioamnionitis. Clin Microbiol Rev 2016; 30: 349–379.
21. Willet KE, Jobe AH, Ikegami M, et al. Antenatal endotoxin and glucocorticoid effects on lung morphometry in preterm lambs. Pediatr Res 2000; 48: 782–788.
22. Kramer BW, Ladenburger A, Kunzmann S, et al. Intravenous lipopolysaccharide-induced pulmonary matur-
ation and structural changes in fetal sheep. *Am J Obstet Gynecol* 2009; 200: 195.
23. Watterberg KL, Demers LM, Scott SM, et al. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. *Pediatrics* 1996; 97: 210–215.
24. Meyer KC and Zimmerman JJ. Inflammation and surfactant. *Paediatr Respir Rev* 2002; 3: 308–314.
25. Hartling L, Liang Y and Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dys-
plasia: a systematic review and meta-analysis. *Arch Dis Child Fetal Neonatal Ed* 2012; 97: F8–F17.
26. Kramer BW, Kaemmerer U, Kapp M, et al. Decreased expression of angiogenic factors in placentas with chorioamnionitis after preterm birth. *Pediatr Res* 2005; 58: 607–612.
27. Kramer BW. Antental inflammation and lung injury: prenatal origin of neonatal disease. *J Perinatol* 2008; 28: S21–S27.
28. Ikegami M and Jobe AH. Postnatal hyperoxia accelerates lung growth and attenuates pulmonary hypertension in infant rats after exposure to intra-amniotic endotoxin. *Am J Physiol Lung Cell Mol Physiol* 2010; 299: L735–L748.
29. Bersani I, Thomas W and Speer CP. Chorioamnionitis – the good or the evil for neonatal outcome? *J Matern Fetal Neonatal Med* 2012; 25: 12–16.
30. Erdemir G, Kultursay N, Calkavur S, et al. Histologic chorioamnionitis: effects on premature delivery and neonatal pro-
gnosis. *Pediatr Neonatol* 2013; 54: 267–274.
31. Berenz A, Vergales JE, Swanson JR, et al. Evidence of early pulmonary hypertension is associated with increased mortality in very low birth weight infants. *Am J Perinatol* 2017; 34: 801–807.
32. Mirza H, Ziegler J, Ford S, et al. Pulmonary hypertension in preterm infants: prevalence and association with bronchopul-
monary dysplasia. *J Pediatr* 2014; 165: 909–914.
33. Kinsella JP, Ivy DD and Abman SH. Pulmonary vasodilator therapy in congenital diaphragmatic hernia: acute, late, and chronic pulmonary hypertension. *Semin Perinatol* 2005; 29: 123–128.
34. Bhat R, Salas AA, Roster C, et al. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. *Pediatrics* 2012; 129: e682–e689.
35. Kallapur SG, Bachurski CJ, Le Cras TD, et al. Vascular changes after intra-amniotic endotoxin in preterm lamb lungs. *Am J Physiol Lung Cell Mol Physiol* 2004; 287: L1178–L1185.
36. Mourani PM, Sontag MK, Younoszai A, et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2015; 191: 87–95.
37. Tang JR, Seedorf GJ, Muehlethaler V, et al. Moderate postnatal hyperoxia accelerates lung growth and attenuates pulmonary hypertension in infant rats after exposure to intra-amniotic endotoxin. *Am J Physiol Lung Cell Mol Physiol* 2010; 299: L735–L748.
38. Nobile S, Marchionni P and Carnielli VP. Neonatal outcome of small for gestational age preterm infants. *Eur J Pediatr* 2017; 176: 1083–1088.
39. Hayward CE, Lean S, Sibley CP, et al. Placental adaptation: What can we learn from birthweight:placental weight ratio? *Front Physiol* 2016; 7: 28.
40. Nyp MF, Taylor JB, Norberg M, et al. Impaired growth at birth and bronchopulmonary dysplasia classification: beyond small for gestational age. *Am J Perinatol* 2015; 32: 75–82.
41. Lio A, Rosati P, Pastorino R, et al. Fetal Doppler velocimetry and bronchopulmonary dysplasia risk among growth-
restricted preterm infants: an observational study. *BMJ Open* 2017; 7: e015232.